Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen

Medicine and Dentistry

• Immune Response 100%
• Cytokine 100%
• Oral Cavity 100%
• Neoadjuvant Immunotherapy 100%
• Gene Expression 50%
• Neoplasm 50%
• Mouth Carcinoma 50%
• Immunotherapy 50%
• DNA Methylation 50%
• Biological Product 25%
• Tumor Invasion 25%
• Primary Tumor 25%
• Low Drug Dose 25%
• Head and Neck Cancer 25%
• Cell Count 25%
• T Lymphocyte 25%
• Alpha 1 Antitrypsin 25%
• Squamous Cell Carcinoma 25%
• Phase II Trials 25%
• Indometacin 25%
• Cyclophosphamide 25%
• Cancer Immunotherapy 25%
• Lymphocytic Infiltration 25%
• Immune-Related Gene 25%
• Methylation 25%
• Omeprazole 25%
• Tumor Suppressor Protein 25%
• Oral 25%

Immunology and Microbiology

• Immune Response 100%
• Cytokine 100%
• Neoadjuvant Immunotherapy 100%
• Gene Expression 50%
• Immunotherapy 50%
• DNA Methylation 50%
• Immune-Related Gene 25%
• Neck 25%
• Squamous Cell 25%
• Low Drug Dose 25%
• Cell Count 25%
• Biological Product 25%
• T Cell 25%
• Cancer Immunotherapy 25%
• Cyclophosphamide 25%
• Methylation 25%
• Alpha 1-Antitrypsin 25%
• Lymphocyte 25%
• Indometacin 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Cytokine 100%
• Immunotherapy 100%
• Neoplasm 75%
• Mouth Carcinoma 50%
• Tumor Suppressor Protein 25%
• Phase II Trials 25%
• Omeprazole 25%
• Tumor Invasion 25%
• Squamous Cell Carcinoma 25%
• Alpha 1 Antitrypsin 25%
• Cyclophosphamide 25%
• Biological Product 25%
• Indometacin 25%
• Lymphocytic Infiltration 25%
• Head and Neck Cancer 25%
• Primary Tumor 25%